TY - JOUR
T1 - Open issues in transcatheter aortic valve implantation. Part 2: procedural issues and outcomes after transcatheter aortic valve implantation
AU - Bax, JJ
AU - Delgado, V
AU - Bapat, V
AU - Baumgartner, H
AU - Collet, JP
AU - Erbel, R
AU - Hamm, C
AU - Kappetein, Arie-Pieter
AU - Leipsic, J
AU - Leon, MB
AU - MacCarthy, P
AU - Piazza, Nick
AU - Pibarot, P
AU - Roberts, WC
AU - Rodes-Cabau, J
AU - Serruys, PWJC (Patrick)
AU - Thomas, M
AU - Vahanian, A
AU - Webb, J
AU - Zamorano, JL
AU - Windecker, S
PY - 2014
Y1 - 2014
N2 - This article provides an overviewon procedure-related issues and uncertainties in outcomes after transcatheter aortic valve implantation (TAVI). The different access sites and how to select them in an individual patient are discussed. Also, the occurrence and potential predictors of aortic regurgitation (AR) after TAVI are addressed. The different methods to quantify AR are reviewed, and it appears that accurate and reproducible quantification is suboptimal. Complications such as prosthesis-patient mismatch and conduction abnormalities (and need for permanent pacemaker) are discussed, as well as cerebrovascular events, which emphasize the development of optimal anti-coagulative strategies. Finally, recent registries haveshown the adoption ofTAVI in the real world, but longer follow-up studies are needed to evaluate the outcome (but also prosthesis durability). Additionally, future studies are briefly discussed, which will address the use of TAVI in pure AR and lower-risk patients.
AB - This article provides an overviewon procedure-related issues and uncertainties in outcomes after transcatheter aortic valve implantation (TAVI). The different access sites and how to select them in an individual patient are discussed. Also, the occurrence and potential predictors of aortic regurgitation (AR) after TAVI are addressed. The different methods to quantify AR are reviewed, and it appears that accurate and reproducible quantification is suboptimal. Complications such as prosthesis-patient mismatch and conduction abnormalities (and need for permanent pacemaker) are discussed, as well as cerebrovascular events, which emphasize the development of optimal anti-coagulative strategies. Finally, recent registries haveshown the adoption ofTAVI in the real world, but longer follow-up studies are needed to evaluate the outcome (but also prosthesis durability). Additionally, future studies are briefly discussed, which will address the use of TAVI in pure AR and lower-risk patients.
U2 - 10.1093/eurheartj/ehu257
DO - 10.1093/eurheartj/ehu257
M3 - Article
VL - 35
SP - 2639-+
JO - European Heart Journal
JF - European Heart Journal
SN - 0195-668X
IS - 38
ER -